Welcome to our dedicated page for Dariohealth news (Ticker: DRIO), a resource for investors and traders seeking the latest updates and insights on Dariohealth stock.
DarioHealth Corp. develops digital health and digital therapeutics solutions for people managing chronic conditions. The company’s multi-condition platform uses data analytics, connected health devices, personalized interventions and one-on-one coaching across diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
DRIO news commonly covers quarterly financial results, conference calls, commercial activity with health plans, payers, self-insured employers, care providers and consumers, and clinical research based on real-world platform data. Other recurring updates include AI-enabled product development such as DarioIQ, evidence publications, board and governance changes, and capital or credit arrangements supporting the company’s digital health business.
DarioHealth Corp. (Nasdaq: DRIO) has been chosen as a digital health provider by Alabama Regional Medical Services (ARMS), a Federally Qualified Health Center focused on hypertension management. This partnership aims to utilize Dario's Remote Patient Monitoring (RPM) technologies to improve health outcomes for underserved populations in Alabama, where over 40% report high blood pressure. This contract marks Dario's second recent win in the RPM sector. The alliance is expected to enhance clinical care while supporting financial goals for ARMS.
DarioHealth Corp. (Nasdaq: DRIO) will have its Chief Medical Officer, Omar Manejwala, M.D., present at the DTx Europe virtual conference on July 14, 2021, at 5:55 a.m. EST. His presentation, titled "Rebalancing: Digital Therapeutics in a Post-Pandemic Healthcare System," will address the evolving role of digital therapeutics post-pandemic. The conference focuses on defining the success of digital therapeutics, emphasizing how these solutions can effectively manage health outcomes and costs. DarioHealth aims to enhance health management through its innovative digital therapeutics platform.
Summary not available.
DarioHealth Corp. (Nasdaq: DRIO) presented new clinical research at the ADA 81st Scientific Sessions, highlighting the effectiveness of its AI-driven personalization engine. The study involved 9,794 users, showing a 56% increase in engagement and a 12% reduction in average high-blood glucose readings over six months. A second study with 11,101 Type 2 diabetes members revealed a significant rise in target in-range readings from 28.4% to 54.8% over a year. These findings underscore Dario's commitment to enhancing health management through tailored interventions.
DarioHealth Corp. (Nasdaq: DRIO) has been selected as the digital health provider for Coastal Family Health Center, focusing on Remote Patient Monitoring (RPM) for hypertension. This initiative targets the high rate of hypertension in Mississippi, enabling better management for over 4,500 patients. Dario's AI-driven platform enhances patient-provider interactions and aims to reduce cardiac events and hospital admissions. The company plans to announce more B2B clients shortly, reinforcing its market position in digital therapeutics.
DarioHealth Corp. (NASDAQ: DRIO) has launched the Upright GO S, a wearable sensor designed to enhance back health accessibility. This product aligns with Dario's growth strategy, targeting both business partnerships and consumer markets. Currently, Dario boasts over 185,000 platform members. The Upright GO S aims to meet the rising demand for affordable musculoskeletal care, particularly as chronic back pain becomes prevalent among lower socioeconomic groups. The device is expected to diversify user engagement by utilizing AI-driven personalization, enhancing user experience across demographics.
DarioHealth Corp. (Nasdaq: DRIO) announced its inclusion in the Russell 3000® and Russell 2000® Indexes, effective June 28, 2021, following the annual reconstitution. This inclusion reflects Dario's growth as a pioneer in digital therapeutics and is expected to enhance company visibility among institutional investors, as approximately $9 trillion in assets are benchmarked to Russell indexes. CEO Erez Raphael highlighted the achievement as a testament to the team's efforts in revolutionizing chronic disease management through AI-powered solutions.
DarioHealth Corp. (Nasdaq: DRIO) has completed the acquisition of PsyInnovations, Inc. (wayForward) for $30 million, comprising $6 million in cash and up to $24 million in stock, contingent on meeting revenue targets in 2022. Approximately 898,500 shares will be issued at a price of $21.09 per share, with an additional 237,000 shares available based on performance. The founders of PsyInnovations will join DarioHealth, bringing expertise in behavioral health, enhancing Dario's digital therapeutic offerings.
DarioHealth Corp. (NASDAQ: DRIO) announced results from a study presented at the 14th International Conference on Advanced Technologies and Treatments for Diabetes. The research focused on the effects of Dario's personalized digital interventions on diabetes self-management, involving 246 users. Key findings included a 14% and 22% increase in the percentage of users measuring blood glucose within the first 30 days and 30-60 days, respectively, along with improvements in measurement frequency and recency. Experts emphasized the potential life-changing benefits of these personalized solutions for diabetes management.
DarioHealth Corp. (Nasdaq: DRIO) announced its participation in the Stifel 2021 Virtual Cross Sector Insight Conference, scheduled for June 9, 2021, at 8:00 a.m. ET. CEO Erez Raphael and President Rick Anderson will present in a virtual format. Interested attendees can access both live and archived webcasts via DarioHealth's investor website. DarioHealth is a leader in digital therapeutics, offering AI-powered solutions that help individuals manage chronic conditions effectively. The company is expanding its services across various regions and medical conditions.